2 September 2026

University of Amsterdam

UvA robot uses AI to improve medicines such as Ozempic

Improving the effectiveness of peptide-based medicines, such as Ozempic, is a crucial but time-consuming part of drug development. In a new project by the UvA MMD TechHub, researchers are working on an AI-guided, autonomous robot that can carry out this process independently and more quickly.

Researchers working on the effectiveness of peptides often face long, repetitive and sometimes hazardous laboratory work, for instance when handling harmful substances. Chemist Timothy Noël previously developed RoboChem, an autonomous synthesis robot that uses AI to speed up the discovery of new molecules and can optimise around ten to twenty small molecules a week, work that would take a PhD candidate months. AI mainly helps the robot quickly identify which chemicals reinforce each other and which work against each other, something humans typically have to study one factor at a time.

In the new MMD TechHub project, Noël is working with assistant professor Andrea Gargano and associate professor Bob Pirok to adapt the robot, renamed RoboBioConjugator, for peptide optimisation. Because peptides are much larger molecules than the substances RoboChem currently works with, this requires integrated analytical instruments and a different approach, making Gargano and Pirok’s expertise in peptide analysis essential.

Read also

ABN AMRO partners with French AI company Mistral

5 August 2026

Amsterdam UMC-led consortium secures €6.1M for AI in medical imaging project

8 January 2024

Protests against AI are growing: ‘Bizarre implications if it becomes smarter than us’

24 May 2026

Subscribe to our newsletter

Would you like to stay informed about what is happening within the Amsterdam AI ecosystem?